Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European ...

Halozyme (HALO) says the European Commission OK'd an injectable version of J&J's (JNJ) cancer drug, Rybrevant for certain ...

Following hot on the heels of Monday’s European Commission EC approval of an indication extension for Johnson & Johnson’s ...

The company continues to focus on its Innovative Medicine segment, which includes promising treatments like RYBREVANT plus LAZCLUZE for lung cancer. This article was generated with the support of ...

This formulation, developed by Janssen-Cilag International NV, a Johnson & Johnson company, combines RYBREVANT® (amivantamab) and LAZCLUZE® (lazertinib) for first-line treatment in adult patients with ...

This formulation, developed by Janssen-Cilag International NV, a Johnson & Johnson company, combines RYBREVANT® (amivantamab) and LAZCLUZE® (lazertinib) for first-line treatment in adult ...

AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and Lazcluze ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to AstraZeneca's Tagrisso in a head-to-head trial, claiming what could be a key ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

In terms of analyst ratings, RBC Capital Markets has maintained its Outperform rating on Johnson & Johnson with a price target of $181, highlighting the potential of the RYBREVANT plus LAZCLUZE ...